Study Comparing Muraglitazar With Glimepiride in Type 2 Diabetics Who Are Not Controlled With Metformin Alone

Bristol-Myers Squibb1,752 enrolled

Overview

The purpose of this clinical research study is to learn whether a muraglitazar-metformin combination is at least as effective as a glimepiride-metformin combination to treat type 2 diabetics who are not sufficiently controlled with metformin alone. The safety of this treatment will also be studied.

Study Type

INTERVENTIONAL

Allocation

RANDOMIZED

Purpose

TREATMENT

Masking

DOUBLE

Enrollment

1,752

Conditions

Diabetes Mellitus, Type 2

Interventions

muraglitazarDRUG

Eligibility

Sex: ALLMin age: 18 YearsMax age: 70 Years

Medical Language ↔ Plain English

Inclusion Criteria: * Subject with Type 2 diabetes receiving treatment with at least 1,500 mg but not greater than 3000 mg of stable metformin therapy for at least 6 weeks prior to screening * HbA1c \>or = 7% and \< or = 10% * Fasting c-peptide \> or = 1.0 umol * Body Mass Index \< or = 41 kg/m2 * Mean serum triglycerides \< or = 600 mg/dl

Locations (206)

Outcomes

Primary Outcomes

Change in baseline HbA1c after 52 weeks

Secondary Outcomes

Change in lipids after 52 weeks; safety and efficacy when administered with metformin after 52 weeks

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.

Local Institution

Birmingham, Alabama, United States

Local Institution

Mesa, Arizona, United States

Local Institution

Phoenix, Arizona, United States

Local Institution

Tucson, Arizona, United States

Local Institution

Fayetteville, Arkansas, United States

Local Institution

Jonesboro, Arkansas, United States

Local Institution

Little Rock, Arkansas, United States

Local Institution

Sherwood, Arkansas, United States

Local Institution

Artesia, California, United States

Local Institution

Bellflower, California, United States

...and 196 more locations